-
Article
Open AccessMulti-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases
Melanoma brain metastases (MBM) are clinically challenging to treat and exhibit variable responses to immune checkpoint therapies. Prior research suggests that MBM exhibit poor tumor immune responses and are e...
-
Article
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial
In this randomized phase 2 trial, blockade of cytotoxic T-lymphocyte protein 4 (CTLA-4) with continuation of programmed death protein 1 (PD-1) blockade in patients with metastatic melanoma who had received fro...
-
Chapter
Melanoma
Rapid growth of translational research in the biology and immunology of melanoma has set the stage for improvements in therapy ranging from surgical procedures (reduced in extent, thus improving morbidity and ...
-
Reference Work Entry In depth
Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy
Melanoma has a very high propensity to metastasize to the central nervous system (CNS), including the brain and leptomeninges. Neurosurgery and stereotactic radiosurgery represent valuable and effective modali...
-
Living Reference Work Entry In depth
Melanoma Brain Metastases: Unique Biology and Implications for Systemic Therapy
Melanoma has a very high propensity to metastasize to the central nervous system (CNS), including the brain and leptomeninges. Neurosurgery and stereotactic radiosurgery represent valuable and effective modali...
-
Article
Open AccessHuman breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression
Functional CD8+ T cells in human tumors play a clear role in clinical prognosis and response to immunotherapeutic interventions. PD-1 expression in T cells involved in chronic infections and tumors such as melano...
-
Article
Open Access31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts
-
Article
Open Access31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one
-
Article
Open Access29th Annual meeting of the Society for Immunotherapy of Cancer (SITC)
The 29th annual meeting of the Society for Immunotherapy of Cancer (SITC) was held November 7-9, 2014 in National Harbor, MD and was organized by Dr. Arthur A. Hurwitz (National Cancer Institute), Dr. Kim A. Marg...
-
Article
Open AccessCITN-06: a Phase I/expansion trial of alt-803, an IL-15 superagonist, in patients with advanced melanoma
-
Article
Open AccessAdoptively transferred melanoma-reactive CTL primed in the presence of IL-21 and transferred with concurrent CTLA4 blockade results in enhanced CTL persistence and tumor regression
-
Article
Open AccessThe Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma
Immunotherapy is associated with durable clinical benefit in patients with melanoma, and this consensus statement outlines recommendations for its use. The panel has based their guidance on the available evide...
-
Article
Open AccessFuture perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”
Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving targeted and immune-based treatments for melanoma. After decades of unsuccessful attempts to finding a more...
-
Chapter
Cytokines in the Treatment of Cancer
Cytokines are molecular mediators of intercellular signaling that function to regulate homeostasis of the immune system. There are five families of cytokines classified by their receptor usage. The effects of ...
-
Article
Open AccessA novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies
While there has been significant progress in advancing novel immune therapies to the bedside, much more needs to be done to fully tap into the potential of the immune system. It has become increasingly clear t...
-
Article
Tumor-Infiltrating Lymphocytes in Melanoma
Adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) is arguably the most effective treatment for patients with metastatic melanoma. With higher response rates than ipilimumab or IL-2, and longer d...
-
Article
Adoptive T-Cell Therapy of Melanoma Using Designer T-Cell Receptors
-
Article
Treatment of Advanced Melanoma with Immunological Checkpoint Block
-
Article
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors
This study was designed to ascertain the dose-limiting toxicities (DLT) and maximally tolerated doses of the combination of fixed-dose tamoxifen and carboplatin, with escalating doses of topotecan, and to dete...
-
Article
Open AccessSummary of the primer on tumor immunology and the biological therapy of cancer
The International Society for Biological Therapy of Cancer (iSBTc) is one of the "premier destinations for interaction and innovation in the cancer biologics community". It provides a primer course each year d...
